Loading in 2 Seconds...
Loading in 2 Seconds...
According to the latest market report published by Credence Research, Inc. “Erythropoietin\nDrugs Market - Growth, Future Prospects, and Competitive Analysis, 2017 -\n2025,” the global erythropoietin drugs market was valued at US$ 9,097.7 Mn in 2016, and is\nexpected to reach US$ 19,653.2 Mn by 2025
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
“Erythropoietin Drugs Market- Growth, Share, Opportunities, Competitive
Analysis, and Forecast 2016 – 2023”
According to the latest market report published by Credence Research, Inc. “Erythropoietin
2025,” the global erythropoietin drugs market was valued at US$ 9,097.7 Mn in 2016, and is
expected to reach US$ 19,653.2 Mn by 2025, expanding at a CAGR of 9% from 2017 to 2025.
Browse the full report Erythropoietin Drugs Market - Growth, Future Prospects and
According to the Centers for Disease Control and Prevention (CDC), around 5.5 Mn ambulatory
care patients suffer from anemia due to a nutritional deficiency, while chronic disease is the
second most prevalent cause. Even though anemia is a common symptom in chronic disease,
it still goes underdiagnosed and undertreated, especially in chronic kidney disease (CKD)
patients not undergoing dialysis anemia is undertreated. In U.S., around 20 Mn people suffer
from CKD, out of which 2-4 million have anemia. Anemia increases substantial economic
burden and also affects quality of life. Rising incidence of CKD, cancer and HIV is the major
factor fuelling the demand of erythropoietin drugs. Advancement in recombinant DNA
technology has led to introduction of different forms of drugs such as epoetin-beta,
darbepoetin-alfa and others. Biologics currently dominate the erythropoietin drugs market; but
the entry of novel drugs with biosimilar formulations with better efficacy and cost effectiveness
would present lucrative opportunities. Biosimilars would be a fast growing market, especially
in developing countries in Asia Pacific and Middle East & Africa, due to low cost therapeutics
and enhanced efficacy.
The global erythropoietin drugs market is segmented by drug type into epoetin-alfa, epoetin-
beta, darbepoetin-alfa and others. Epoetin-alfa dominates the global erythropoietin drugs
market, since it is the first biologic for anemia caused due to kidney disease, cancer or HIV
and is widely accepted by physicians. The global erythropoietin drugs market is segmented by
application type into anemia (cancer and HIV), kidney disorders (ESRD and dialysis) and
others (neural diseases, wound healing and others). Renal disease occupies a large share of
the market due to the reported increase in prevalence of kidney disorders.
As of the current market scenario, North America dominated the global erythropoietin drugs
market followed by the European market. Rising prevalence of renal disease, cancer and HIV,
well established research and healthcare infrastructure, favorable reimbursement policies are
the key factors driving the North American market. Additionally, major biopharmaceutical.....
Browse the full Erythropoietin Drugs Market - Growth, Future Prospects and Competitive Analysis,
2017 – 2025 report at http://www.credenceresearch.com/report/erythropoietin-drugs-market
Credence Research is a worldwide market research and counseling firm that serves driving organizations,
governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with
making enduring enhancements to their execution and understand their most imperative objectives. Over almost
a century, we've manufactured a firm extraordinarily prepared for this task.
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US